NCT07271693

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants

A Phase I, Randomized, Investigator/Participant-blind, Parallel-group, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 128 (estimated)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of single and multiple ascending doses of RO7806881 in healthy participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	RO7806881	RO7806881 will be administered as per the schedule specified in the protocol.
DRUG	Placebo	Placebo will be administered as per the schedule specified in the protocol.

Timeline

• Start date: 2025-12-22
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2025-12-09
• Last updated: 2026-04-15

Locations

1 site across 1 country: New Zealand